君實生物(01877.HK):LY-CoV016聯合療法在降低冠狀病毒住院及急診治療方面顯示出良好療效
格隆匯10月7日丨君實生物(01877.HK)發佈公告,對BLAZE-1研究(NCT04427501)所進行的一項新期中分析數據顯示,LY-CoV555及JS016(LY-CoV016)的聯合療法(其結合SARS-CoV-2刺突蛋白的抗原表位治療有症狀COVID-19門診患者)在降低病毒載量、減輕症狀及降低和冠狀病毒相關的住院及急診治療方面均顯示出良好療效。
該聯合療法顯著降低了第11天的病毒載量(p=0.011),達到了該研究的主要終點。此外,該聯合療法降低了第3天(p=0.016)及第7天(p<0.001)(感染過程中較早的時間點,通常能觀察到更高的病毒載量)的病毒水平。該聯合療法亦達到預設的臨牀終點,包括自第1至11天的症狀總體評分相較於基線的時間加權平均變化。目前以聯合療法治療的患者中未觀察到推測的耐藥變異。聯合療法的耐受性良好且概無發生與藥物有關的嚴重不良事件(SAEs),且治療中突發不良事件(TEAEs)與安慰劑相當。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.